BFRI - Enrollment underway in Biofrontera's mid-stage study of Ameluz + BF-RhodoLED for acne treatment

Biofrontera (BFRI +18.6%) announces that the first subject has been enrolled in the Phase 2b study to evaluate the safety and efficacy of Ameluz in combination with the red-light lamp BF-RhodoLED for the treatment of moderate-to-severe acne with photodynamic therapy (Ameluz-PDT). The study will enroll 126 patients. The efficacy of Ameluz-PDT will be tested with respect to incubation periods of one and three hours compared to placebo. The composite primary endpoint is the absolute change in the number of inflammatory lesions and an improvement in symptoms. This study is an important component of Biofrontera's clinical development strategy that aims to expand the FDA-label of our licensed product Ameluz.

For further details see:

Enrollment underway in Biofrontera's mid-stage study of Ameluz + BF-RhodoLED for acne treatment